Breakdown | |||||
TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
29.09M | 31.91M | 31.06M | 107.07M | 117.73M | 76.02M | Gross Profit |
13.27M | 14.63M | 11.57M | 41.97M | 53.58M | 23.77M | EBIT |
-8.69M | -9.82M | -24.74M | -15.51M | 9.88M | -23.64M | EBITDA |
-7.36M | -8.35M | -20.94M | -15.01M | 3.35M | -27.59M | Net Income Common Stockholders |
-21.31M | -26.08M | 20.29M | -22.58M | 3.42M | -33.89M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
31.56M | 52.37M | 82.37M | 21.60M | 43.50M | 47.87M | Total Assets |
115.45M | 85.76M | 121.88M | 95.86M | 113.69M | 112.54M | Total Debt |
0.00 | 3.51M | 7.00M | 20.59M | 22.68M | 32.79M | Net Debt |
-8.75M | -48.86M | -75.38M | -1.02M | 9.15M | -15.07M | Total Liabilities |
18.52M | 29.65M | 43.42M | 41.40M | 45.10M | 54.16M | Stockholders Equity |
96.92M | 56.11M | 78.46M | 54.46M | 68.59M | 58.38M |
Cash Flow | Free Cash Flow | ||||
-15.75M | -26.80M | -39.74M | -20.06M | -4.05M | -19.35M | Operating Cash Flow |
-14.96M | -26.26M | -36.98M | -16.59M | 387.00K | -17.18M | Investing Cash Flow |
4.22M | -545.00K | 98.98M | 25.22M | -34.50M | -2.17M | Financing Cash Flow |
-9.18M | -4.19M | -1.13M | -241.00K | -242.00K | 7.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $5.20B | 3.26 | -40.34% | 2.93% | 17.68% | 1.94% | |
47 Neutral | $16.77M | ― | -12.94% | ― | ― | ― | |
46 Neutral | $182.34M | ― | -270.01% | ― | -65.96% | 40.80% | |
45 Neutral | $22.79M | ― | -115.06% | ― | 1.64% | 50.63% | |
36 Underperform | $19.57M | ― | -55.95% | ― | ― | 32.42% | |
35 Underperform | $20.21M | ― | -164.30% | ― | ― | 44.38% | |
28 Underperform | $25.43M | ― | -2880.11% | ― | ― | 24.35% |
On March 28, 2025, Enzo Biochem announced its decision to voluntarily delist its common stock from the New York Stock Exchange (NYSE) and move to the OTCQX Best Market. This strategic shift follows a notice from the NYSE regarding non-compliance with listing standards related to market capitalization, stockholder’s equity, and average closing stock price. The company plans for the delisting to be effective around April 17, 2025, with trading on OTCQX expected to begin on April 18, 2025. Enzo Biochem aims to ensure a smooth transition for shareholders, maintaining electronic trading without disruption and continuing to meet periodic reporting requirements under the Securities Exchange Act of 1934.